Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1552 Trials   75151 News 


«12...4041424344454647484950...858859»
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Preclinical, Journal:  Human plasma cells engineered to secrete bispecifics drive effective in (Pubmed Central) -  Aug 8, 2024   
    Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Jun 2024 | Trial primary completion date: Sep 2024 --> Jun 2024 Finally, the steady-state concentration of anti-CD19 bispecifics in serum 1
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  PLGA Nanoplatform for the Hypoxic Tumor Delivery: Folate Targeting, Therapy, and Ultrasound/Photoacoustic Imaging. (Pubmed Central) -  Aug 8, 2024   
    Here, we have introduced Palbociclib (PCB)-loaded PLGA nanoparticles (NPs) consisting of chitosan-folate (CS-FOL) for folate receptor-targeted breast cancer therapy...In vitro cellular uptake study in MCF-7 cells confirmed the receptor-mediated endocytosis of targeted NPs. In vivo ultrasound and photoacoustic imaging studies on rats with hypoxic breast cancer showed that targeted NPs significantly reduced tumor growth and hypoxic tumor volume, and suppressed angiogenesis.
  • ||||||||||  Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
    Review, Journal, IO biomarker:  The next-generation KRAS inhibitors (Pubmed Central) -  Aug 7, 2024   
    Additionally, immunological approaches utilizing T-cell receptor (TCR)-engineered T cell therapy or vaccines, and Hapimmune antibodies are ongoing. This review delineates the recent advancements in KRAS inhibitor development in the post-sotorasib/adagrasib era, with a focus on NSCLC.
  • ||||||||||  ONX 0914 / Protalex, Amgen
    Preclinical, Journal:  Geraniol (GER) attenuated chronic sleep restriction (CSR)-induced neuroinflammation in adolescent mice. (Pubmed Central) -  Aug 7, 2024   
    ONX-0914 was applied to inhibit LMP7 selectively, and data validated that GER might alleviate CSR-induced neuroinflammation by regulating LMP7. Our study provides evidence that LMP7 is a critical regulator of CSR-induced proinflammation, and geraniol might be a promising therapy against CSR-induced neurodevelopmental disorders.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Review, Journal:  Beyond quadruple therapy: the potential roles for ivabradine, vericiguat, and omecamtiv mecarbil in the therapeutic armamentarium. (Pubmed Central) -  Aug 7, 2024   
    Thus, ranolazine and ivabradine exhibit the properties of voltage-gated Na+ channel blockers mainly in smooth muscles of pulmonary arterial vessels and promote the decrease in endothelial permeability. Vericiguat could be considered for high-risk patients who have recently experienced worsening heart failure events despite being on quadrable therapy, but they should not have N-terminal pro-B-type natriuretic peptide levels exceeding 8000
  • ||||||||||  Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis, Rituxan (rituximab) / Roche
    Review, Journal:  Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management. (Pubmed Central) -  Aug 6, 2024   
    Although IVIGand prednisone usually suffice to achieve hemostasis for delivery, second-lineagents are sometimes required to allow for neuraxial anesthesia. There isgrowing evidence supporting the use of romiplostim during pregnancy; however,its risk of venous thromboembolism warrants further evaluation.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal, Surgery:  The potential effect of romosozumab on perioperative management for instrumentation surgery. (Pubmed Central) -  Aug 6, 2024   
    Romosozumab significantly increased the regional vBMD as well as biomechanical parameters, potentially offering clinical benefits in reducing post-operative complications in patients with osteoporosis undergoing orthopedic instrumentation surgery. This study highlights the novel advantages of romosozumab treatment and advocates further research on its effectiveness in perioperative management.
  • ||||||||||  Thalagen (autologous CD34+ cells transduced with TNS9.3.55) - San Rocco Therap, Memorial Sloan / Kettering Cancer Center
    Trial completion date, Trial primary completion date, Viral vector:   (clinicaltrials.gov) -  Aug 6, 2024   
    P1,  N=10, Active, not recruiting, 
    Phase classification: P1b/2 --> P1/2 Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
  • ||||||||||  Nplate (romiplostim) / Amgen
    Perioperative anesthesia management of a patient with Evans syndrome (Exhibit Hall) -  Aug 6, 2024 - Abstract #ASA2024ASA_5543;    
    Post-operatively, platelets improved to 118k with no hemolysis. Given the rarity of Evans syndrome, the literature is sparse regarding perioperative anesthetic management of Evans Syndrome, highlighting the value of such reports for this complex condition.
  • ||||||||||  Prolia (denosumab) / Amgen
    Clinical, Journal:  Bone-Active Drugs in Pre-Menopausal Women with Breast Cancer Under Hormone Deprivation Therapies. (Pubmed Central) -  Aug 5, 2024   
    Premenopausal women under HDTs are at high risk of VFs in relationship with high BMI, densitometric diagnosis of osteoporosis, preexisting VFs, and family history of osteoporotic fractures. Vertebral fractures in this setting might be effectively prevented by bisphosphonates or denosumab.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Trajectories of switching to optimise efficacy and minimising risks in patients with moderate-to-severe plaque psoriasis: results from the PsoReal registry. (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_5054;    
    Through these innovative methods which may be of example for other countries, we found that switching from a conventional to a biological agent as well as between different biologics, represents the best strategy to optimise efficacy and minimising risks. Certainly, larger studies encompassing different national registries and conducted by applying these original methods, may be required to analyze the specific national trajectories of switching and to confirm the trajectories and patterns of switching detected in our cohort of patients.
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
    Efficacy of Ixekizumab in patients of psoriasis with treatment failure in South Asian population (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_5039;    
    It is approved for the treatment of patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Compared to the other biologics available in our country, it has a faster onset of action and provides rapid relief to the patients.
  • ||||||||||  Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen
    Rupioid Psoriasis in Childhood: a challenging case report. (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_4990;    
    In addition, the disease has a high social impact at all ages, but tends to be worse in children. Knowing the best alternatives for each case and possibilities for exchange if refractory, as well as how to manage high-response drugs such as immunobiologicals, is extremely important to restore as soon as possible the patient
  • ||||||||||  Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
    Patients with a history of neoplasia and psoriasis under treatment with Tildrakizumab: series of 48 cases (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_4924;    
    Tildrakizumab has been associated with high efficacy and a good long- term safety profile, with low sustained rates of malignant tumors, in clinical trials with extension phases up to 5 years. However, real-world data are needed to understand the safety of biologic treatments in patients with a history of malignant disease.
  • ||||||||||  Paradoxical arthritis induced by IL-17A antagonist in a patient with plaque psoriasis. (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_4803;    
    We transitioned to etanercept, with a good response for 8 years, followed by recurrence of lesions Afterward, a loss of clinical response prompted the initiation of secukinumab, achieving a PASI 90 response by the 8th week...Subsequently, secukinumab was discontinued, and adalimumab was initiated, resulting in complete resolution of arthralgia after 12 weeks...A review described paradoxical PsA in a psoriasis patients treated with ustekinumab ranging from 3 days to 28 months since the onset of the medication. Overall, this case underscores the importance of vigilance for paradoxical reactions in patients receiving immunobiological therapy for psoriasis and highlights the need for further research to better understand the mechanisms underlying these phenomena, specially with Secuquinumab.
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    CARD14-associated papulosquamous eruption: A Diagnostic and Therapeutic Challenge in Dermatology (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_4118;    
    Larger-scale studies are warranted. Initially diagnosed with psoriasis and plaques resistant to treatment with methotrexate, a possible involvement of an autoinflammatory disease was suspected, leading to an approach that included requesting serum markers of infection and inflammation, taking radiographs to assess joint involvement, complete blood count, renal profile, liver profile, and general urine examination, all without anomalies and borderline vitamin D. Psoriatic arthritis was ruled out, and HLA B27 and rheumatoid factor with acute phase reactants were requested, as well as a bone series, all showing no significant alterations...Treatment with etanercept was initiated, resulting in clinical improvement and a notable increase in the patient
  • ||||||||||  Remicade (infliximab) / J&J
    Disseminated Cutaneous Leishmaniasis in a Patient Treated with Infliximab (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_4076;    
    Initially diagnosed with psoriasis and plaques resistant to treatment with methotrexate, a possible involvement of an autoinflammatory disease was suspected, leading to an approach that included requesting serum markers of infection and inflammation, taking radiographs to assess joint involvement, complete blood count, renal profile, liver profile, and general urine examination, all without anomalies and borderline vitamin D. Psoriatic arthritis was ruled out, and HLA B27 and rheumatoid factor with acute phase reactants were requested, as well as a bone series, all showing no significant alterations...Treatment with etanercept was initiated, resulting in clinical improvement and a notable increase in the patient Introduction: We present a 67-year-old male with a history of Crohn
  • ||||||||||  Cosentyx (secukinumab) / Novartis
    Treating Leprosy Reactions with Secukinumab: Pioneering Frontiers in a Secular Disease (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_3959;    
    Cytokines like tumor necrosis factor-alpha (TNF- ?) and IL-6 are implicated in leprosy and LR. Immunobiological drugs, such as etanercept and infliximab, have been used to treat LR as a sparing corticosteroid therapy and for recalcitrant cases.
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen
    Oncolytic Viral Therapy for Non Melanoma Skin Cancers  (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_2919;    
    However, existing studies are notably heterogeneous in the design, study population and response assessment, limiting generalizability. Robust evidence from phase 3 clinical trials demonstrating safety and efficacy of OVs is also lacking at present.